2967 Ondansetron Ondansetron is a well tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drugs use. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system; Ondansetron is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy. Its effects are thought to be on both peripheral and central nerves. One part is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata, the other is a blockage of serotonin receptors in the chemoreceptor trigger zone. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors; A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties; Ondansetron (INN) is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy. Its effects are thought to be on both peripheral and central nerves. One part is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata, the other is a blockage of serotonin receptors in the chemoreceptor trigger zone. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors. 99614-02-5 4595 C18H19N3O 293.152810 White powder. 231 - 232°C Ondansetron is well absorbed after oral administration and undergoes limited first-pass metabolism. Ondansetron is a selective serotonin 5-HT₃ receptor antagonist. The antiemetic activity of the drug is brought about through the inhibition of 5-HT₃ receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT₃ receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone. Hepatic Half Life: 5.7 hours No indication of carcinogenicity to humans (not listed by IARC). For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, postoperation, and radiation. Also used for the treatment of postoperative nausea and vomiting. Low blood pressure and fainting, sudden blindness, severe constipation There is no specific antidote for ondansetron overdose. Patients should be managed with appropriate supportive therapy. (L1712) 2009-07-21T20:27:55Z 2026-05-14T16:52:24Z Ondansetron C07325 103183 Ondansetron DB00904 true CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2 C18H19N3O InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3 FELGMEQIXOGIFQ-UHFFFAOYSA-N 293.363 293.152812245 Exogenous Solid 2.4 HMDB05035 CHEMBL46 4434 <p>Peter Bod, Kalman Harsanyi, Ferenc Trischler, Eva Fekecs, Attila Csehi, Bela Hegedus, Eva Mersich nee Donat, Gyorgyi Szabo nee Komlosi, Erika Horvath nee Sziki, &#8220;Process for preparing ondansetron.&#8221; U.S. Patent US5478949, issued September, 1990.</p> CHEM002297 DTXSID8023393 NS00010141 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one 39.82 86.77950000000001 33.16037978817858 2 2 0 15.385697836647786 7.344313880827463 1 4 2.56 -3.07 2.48e-01 g/l